New hope for lung cancer patients: drug shows promise after standard therapy fails
NCT ID NCT06382116
First seen Nov 17, 2025 · Last updated Jun 14, 2026 · Updated 26 times
Summary
This study tests a new drug called BL-B01D1 against standard chemotherapy in 432 people with advanced non-small cell lung cancer whose cancer worsened after initial targeted therapy (EGFR-TKI). The goal is to see if the new drug can slow cancer growth and improve survival. Participants must have a specific EGFR gene mutation and not have had other treatments besides the targeted therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.